Drug guidance
Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis
Condition
Musculoskeletal
1 June 2023
Published on 01 Jun 2023
Last Updated on 01 Jun 2023
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Secukinumab 150 mg/mL solution for injection in prefilled pen for treating adults with active non-radiographic axial spondyloarthritis
Funding status
Secukinumab 150 mg/mL solution for injection in prefilled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.
Secukinumab should be used in line with additional clinical criteria for initial and continuing prescriptions for adult patients with active non-radiographic axial spondyloarthritis.
MAF assistance does not apply to ixekizumab, or any other formulations or strengths of secukinumab.